A possible fifth case of Tysabri [natalizumab]-associated progressive multifocal leukoencephalopathy (PML) has been reported to the US FDA.

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1057, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

There have been no new cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri [natalizumab]

By  

Reactions Weekly, Vol. 1, Iss. 1065, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

No new confirmed cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri [natalizumab]

By  

Reactions Weekly, Vol. 1, Iss. 1075, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

EMEA's CHMP has recommended updating the product information for natalizumab [Tysabri] to further increase the awareness about risk of progressive multifocal leukoencephalopathy (PML)

By  

Reactions Weekly, Vol. 1, Iss. 1222, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Natalizumab: Progressive multifocal leukoencephalopathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1326, 2010-01 ,pp. : 26-26

Adis International

Access to resources Recommend Favorite

Natalizumab: Progressive multifocal leukoencephalopathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1327, 2010-01 ,pp. : 27-28

Adis International

Access to resources Recommend Favorite